Dogwood Therapeutics develops new medicines for pain and neuropathic disorders as a development-stage biopharmaceutical company listed on Nasdaq under DWTX. Company news centers on its pain and neuropathy pipeline, including Halneuron®, a non-opioid NaV 1.7 analgesic in development for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist program for chemotherapy-related pain and neuropathy.
Recurring updates also cover clinical and regulatory developments, FDA designations and investigational-drug activity, intellectual-property work tied to synthetic Halneuron®, financial results, financing activity, shareholder communications, and licensing arrangements involving anti-viral assets such as IMC-1 and IMC-2.
Dogwood Therapeutics (Nasdaq:DWTX) announced that CEO Greg Duncan will participate at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel in New York City.
Mr. Duncan will be available for one-on-one meetings with institutional investors and will meet with senior Maxim analysts during the event. For agenda and registration details, visit www.maximgrp.com/2025-growth-summit.
Dogwood Therapeutics (Nasdaq:DWTX) announced that its Chief Medical Officer will present an overview of the Halneuron® (tetrodotoxin) pain research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025.
Halneuron is a highly purified TTX formulation in development for chemotherapy‑induced neuropathic pain (CINP). A preclinical CINP study found Halneuron and VX‑548 each rapidly suppressed mechanical allodynia, with Halneuron showing comparable or greater pain reduction and the combination showing no additive benefit. Over 700 patients have received TTX in human studies. Halneuron showed pain reduction in prior Phase 2 studies and is being evaluated in a Phase 2b HALT‑CINP trial at 25 U.S. sites to assess low‑dose injectable safety and efficacy.
Dogwood Therapeutics (NASDAQ:DWTX) has secured a worldwide, royalty-free license for SP16, a first-in-class LRP1 agonist, through an all-stock transaction with Serpin Pharma. SP16 will be developed as a treatment for cancer-related pain, specifically focusing on chemotherapy-induced peripheral neuropathy (CIPN).
The National Cancer Institute has fully funded SP16's upcoming Phase 1b CIPN study, with patient enrollment expected to begin in H1 2026. SP16 has shown both anti-inflammatory and neural repair properties in preclinical research, potentially complementing Dogwood's existing drug Halneuron®, which is currently in Phase 2b trials for chemotherapy-induced neuropathic pain with interim data expected in December 2025.
Dogwood Therapeutics (Nasdaq: DWTX), a development-stage biotech company focused on pain and fatigue-related disorders, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The event will take place on September 8-10, 2025 at the Lotte New York Palace Hotel.
CEO Greg Duncan will engage in a fireside chat with H.C. Wainwright's VP of Equity Research, Sean Lee, on September 5, 2025. The presentation will be available on-demand starting at 7:00 AM ET and can be accessed through the company's investor relations website, with the replay available for approximately 90 days.
Dogwood Therapeutics (NASDAQ:DWTX) has reported its Q2 2025 financial results, highlighting progress in its Halneuron® Phase 2b trial for Chemotherapy-Induced Neuropathic Pain (CINP). The company has enrolled 52 patients with a low discontinuation rate of 5.8%, suggesting good tolerability. The interim data readout remains on track for Q4 2025.
The company's pipeline includes Halneuron®, which has received FDA fast track designation for CINP treatment, and IMC-1 for Fibromyalgia. Financial results show R&D expenses of $2.5 million and a net loss of $3.8 million. With $13.4 million cash on hand, Dogwood has operational runway through Q1 2026.
Dogwood Therapeutics (NASDAQ:DWTX) has reached a significant milestone in its Phase 2b clinical trial for Halneuron®, enrolling the first 50 patients to evaluate the drug's effectiveness in treating Chemotherapy-Induced Neuropathic Pain (CINP). The trial, known as HALT-CINP, demonstrates promising early safety data with only a 6% discontinuation rate among the first 35 patients.
The study focuses on cancer patients with neuropathy from platinum or taxane-based chemotherapy, administering 8 daily subcutaneous doses over 14 days with a 28-day follow-up. The company remains on track for its Q4 2025 interim analysis of approximately 100 patients, with full results expected in mid-2026. The trial will be conducted across 25 U.S. sites, evaluating primary endpoints of safety and pain intensity reduction.
Dogwood Therapeutics (Nasdaq: DWTX), a development-stage biotech company focused on developing treatments for pain and fatigue-related disorders, will release its Q2 2025 financial results on Wednesday, August 13, 2025, before market open.
Dogwood Therapeutics (NASDAQ: DWTX) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman Greg Duncan will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Those interested in scheduling meetings can contact John Perez at jperez@dboralcapital.com for registration.